Key Takeaways:
Investors who bought ARS Pharmaceuticals Inc. shares between March 9 and June 24, 2026 have until October 5 to seek lead-plaintiff status in a federal securities class action over the company's CVS Caremark coverage guidance.
The complaint alleges the company and its executives told investors that expanded insurance coverage for neffy, its needle-free epinephrine nasal spray, would take effect July 1, 2026, while disclosing only generalized risk language about that timeline. "Defendants provided these overwhelmingly positive statements to investors while, at the same time, failing to adequately disclose the risk that the expanded insurance coverage may not be available by the July 1 deadline," according to the Robbins LLP notice of the action.
ARS disclosed the reversal after the close on June 24, 2026, saying no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1 cycle and that CVS Caremark had reserved its decision until January 2027. The stock fell $2.52, or 23.9%, to close at $8.02 on June 25 from $10.54 a day earlier, on unusually heavy volume. That single session is the loss event the class period is built around.
The class period runs from March 9, 2026 through June 24, 2026, inclusive, and covers holders of NASDAQ-listed SPRY securities. Under the Private Securities Litigation Reform Act, any investor who purchased during that window may move for appointment as lead plaintiff; courts generally appoint the movant with the largest financial interest who also satisfies Federal Rule of Civil Procedure 23. Participation in any recovery does not require serving in that role, and absent class members keep their claim.
At least two firms are running parallel solicitation campaigns on the same deadline. Faruqi & Faruqi, which has offices in New York, Pennsylvania, California and Georgia, is directing investors to partner Josh Wilson, while Robbins LLP, which says it has restored more than $2 billion in value to shareholders, is routing inquiries through attorney Aaron Dumas, Jr. Both notices carry attorney-advertising disclaimers and neither firm has disclosed a filed damage figure.
The litigation adds legal expense and management distraction to a company whose commercial story now depends on a January 2027 coverage decision rather than the summer and back-to-school allergy seasons it had guided toward. For holders who bought into the July 1 timeline, the case preserves a recovery path but does not reverse the drawdown — SPRY closed at $8.02, roughly 24% below its June 24 level.
The next checkpoint is October 5, 2026, when lead-plaintiff motions are due. Watch for a consolidated complaint and any disclosed settlement framework after that date, and for CVS Caremark's January 2027 formulary decision, which now sets the timeline for neffy's expanded commercial coverage.
This article is for informational purposes only and does not constitute investment advice.
